It's about more than just a single peptide
We have to look at patients holistically, who have kidney disease and diabetes, to address the totality of risks, certainly progression to kidney failure, but also prevention of cardiovascular events and deaths. Ozempic and other GLP-1s will be compared to another diabetes drug class, SGLT-2 inhibitors Given Ozempics reduction of kidney disease events in the FLOW study, it seems likely that the GLP-1s will be used together with and compared against SGLT-2 inhibitor drugs
For this purpose, you can do the following: Arrange a medical consultation with your doctor or book a consultation with your online doctor, such as Eirdoc
A natural product, excellent for use in periods of low immunity, when the body needs additional support
This large-scale evidence supports our narrative review published in 2025, in which we suggested a connection between GLP-1RAs and addiction based on the limited evidence available in the literature at that time
